Advaxis shares soar after FDA lifts clinical hold

Two months after the FDA forced a halt to the development work at Advaxis ($ADXS) following the death of a patient in its cancer vaccine study, the biotech says it has a green light to get back on track. The company's shares soared on the news, jumping 32% in midmorning trading. The clinical hold was prompted after a patient taking axalimogene filolisbac (ADXS-HPV) tested positive for a strain of Lm [Listeria monocytogenes] used in the vaccine. She was treated but later died. The clinical hold also included the INDs for ADXS-PSA and ADXS-HER2. The biotech says that it added some risk mitigation strategies to its study, "including revised study protocol inclusion / exclusion criteria, post-administration antibiotic treatment and patient surveillance and monitoring measures." Release

Suggested Articles

Frontage is Growing to Meet All Your Needs! Click Here to Learn About the Next Generation of Frontage.

Cara Care, a digital health startup focused on digestive diseases, raised $7 million to bring its mobile app to more patients in the U.S.

Investors looked past the headline success of Sci-B-Vac, zeroed in on the failure to achieve a secondary objective and sent VBI’s stock down 66%.